Register Login

Syndax Pharmaceuticals Inc (SNDX)

(90% Positive) SYNDAX PHARMACEUTICALS, INC. (SNDX) Announces Enrollment Update for translocation Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 24, 2025, 8:42 p.m.

    📋 SYNDAX PHARMACEUTICALS, INC. (SNDX) - Clinical Trial Update

    Filing Date: 2025-10-24

    Accepted: 2025-10-24 16:40:19

    Event Type: Clinical Trial Update

    Event Details:

    Syndax Pharmaceuticals Inc (SNDX) Announces Clinical Trial Update Syndax Pharmaceuticals Inc (SNDX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: translocation
    • Collaboration: Exhibit 99.1 Syndax
    • Updated Timeline: October 24, 2025

    🔬 Clinical Development Pipeline (SYNDAX PHARMACEUTICALS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Revumenib DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Intensive Chemotherapy Regimen DRUG Phase PHASE3 Acute Myeloid Leukemias ClinicalTrials.gov
    ASTX727 DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Venetoclax DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    SNDX-5613 DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Procedure/Surgery PROCEDURE Phase PHASE2 Bladder Cancer ClinicalTrials.gov
    Entinostat DRUG Phase PHASE2 Bladder Cancer ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE2 Bladder Cancer ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Acute Myeloid Leukemias ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Syndax Pharmaceuticals Inc
    • CIK: 0001395937
    • Ticker Symbol: SNDX
    • Period End Date: 2025-10-24
    • Document Type: 8-K

Search

News categories